Summary:
- The article discusses a new dual-action drug that could potentially tackle Alzheimer's disease by targeting the tau protein, which is responsible for the formation of neurofibrillary tangles in the brain.
- The drug, developed by researchers at the University of Cambridge, has shown promising results in preclinical studies, demonstrating the ability to both prevent the aggregation of tau and also break down existing tau tangles.
- The researchers believe this dual-action approach could be more effective in treating Alzheimer's compared to existing therapies that only target a single aspect of the disease, and they are now planning to move the drug into clinical trials.